Helical raised $10M to turn biological foundation models into pharma systems

Helical raised $10 million in seed funding to transform biological foundation models from an interesting research technology into working systems for pharmaceutical companies. This is an important signal for the market: investors are betting not just on another AI platform, but on a team that is already deploying its solutions with major clients. For an industry where the cost of mistakes is high, the fact of production use often matters more than loud promises or demos.

The startup is based in London, but its roots are in Luxembourg: the company was founded by three childhood friends from Luxembourg. The $10 million round was led by redalpine fund, and among the angel investors were executives from Cohere and Hugging Face.

Such a lineup of participants is important in itself. It shows that the project is trusted not only by classic venture players, but also by people directly involved in developing modern AI models and infrastructure around them.

The key point in Helical's story is not the size of the round, but the stage of the product. The company already reports working in production with several pharmaceutical groups from the world's top 20, as well as a public partnership with Pfizer. For young AI startups, this is a rare level of validation.

In pharma, new tools are not adopted impulsively: there are long verification cycles, strict requirements for data quality, reproducibility of results, and integration with existing research processes. If a solution has reached real-world use, it means it has passed at least part of the most difficult path.

The very idea of 'turning foundation models into systems' is also telling. A base model can work well in laboratory scenarios and on test datasets, but business needs not abstract capabilities, but concrete tools: a clear interface, reliable pipelines, quality control, compatibility with internal data, and clear decision-making logic.

In biotech and pharma, this gap between model and product is particularly large because it involves complex biology, expensive experiments, and potentially multi-year drug development cycles.

The market typically understands bio foundation models as large models trained on biological sequences, molecular structures, or related sets of scientific data. Their potential has long been discussed as the next major layer of AI after language models, because they can help find connections that are difficult to see manually.

But this approach has limitations: pharma has little use for beautiful predictions on slides; it needs tools that can be verified on internal data and compared with laboratory results.

This is why investors increasingly look not at the 'magical' model per se, but at the team's ability to embed it into a real research chain.

Therefore, Helical's bet looks pragmatic. Instead of selling the market only the promise of 'AI for drug discovery,' the company, judging by its positioning, is building a layer that makes such models suitable for day-to-day work of research teams.

For pharmaceutical companies, this could mean faster analysis of biological data, more convenient pattern search, and more structured work with hypotheses.

For the AI market itself, this is another sign of a shift from the race for the biggest models to the race for systems that actually embed into industry processes. It is precisely this applied part that usually becomes the biggest bottleneck for scaling.

The conclusion is simple: Helical raised a relatively small round by AI boom standards, but compensates for this with the quality of signals: early adoption by major pharmaceutical companies, a public partnership with Pfizer, and a strong roster of investors.

It is precisely at such transitions from research hypothesis to operational tool that new value is being formed in industry AI today.

If the company can prove that its approach consistently delivers value in real R&D processes, interest in applied bio-AI systems in pharma will only grow in the coming years.